Business & Economics

Industry Report: Lotte's Strategic Rise as a Global CDMO Amid Industry Shifts

AbbVie and RemeGen to Jointly Develop a Novel Bispecific Antibody for Advanced Solid Tumors

OBI Pharma Signs Exclusive Licensing Agreement with TegMine Therapeutics for Glycan-Targeting ADC

During the 44th J.P. Morgan Healthcare Conference, held January 12-15, 2026, in San Francisco (USA), Rakuten Medical and LOTTE Biologics signed a manufacturing agreement to strengthen Rakuten Medical's production capabilities for its innovative oncology therapy, Alluminox® platform-based photoimmunotherapy, which has been shown to induce rapid and selective cell killing.

The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China has approved an Investigational New Drug (IND) application for SKB105 (also known as CR-003 and PR-023), integrin beta-6 (ITGB6)-targeted antibody-drug conjugate (ADC) being developed by Sichuan Kelun-Biotech Biopharmaceutical, for the treatment of advanced solid tumors.

By combining antibody specificity with cytotoxic drug potency, antibody-drug conjugates (ADCs) continue to be a promising class of targeted therapies. However, despite significant advancements in the development of ADC, challenges such as limited efficacy, often attributed to tumor heterogeneity and resistance development, remain present. To overcome some of the complexities and challenges in the development of ADCs, Swiss-based Debiopharm and NetTargets, a South Korean biotech company specializing in AI-enhanced systems biology for drug discovery, have agreed to collaborate in developing the next-generation, dual-payload ADCs designed to overcome acquired resistance mechanisms in difficult-to-treat cancers.

Based on a recent analysis published earlier this years DataM Intelligence predict that the market size of the for Antibody-drug Conjugates (ADC) valued at around US $11.9 billion in 2024, is projected to surge past US $30.4 billion by 2033, expanding at a robust CAGR of 11.2% (2025–2033).

The US Food and Drug Administration (FDA) has approved belantamab mafodotin (Blenrep®' GSK; see ADC Drugmap), an antibody-drug conjugate (ADC) comprising a humanized BCMA...

AAX Biotech, founded by experts from Karolinska Institutet in Stockholm, Sweden, and Daiichi Sankyo are collaborating in the evaluation of  AAX Biotech's Opti-mAb®technology. AAX Biotech pioneers...

China’s out-licensing deals have significantly increased over the last five years, showcasing the country as a source of innovative drugs. The licensing agreements provide...